Sana Biotechnology (SANA) catalysts

Upcoming FDA decisions and readouts we track for Sana Biotechnology, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Sana Biotechnology (SANA, listed on Nasdaq). It concerns SG293 (Non-Hodgkin lymphoma (in vivo CAR-T)).

First on the list: the Phase 1 readout for SG293 (Non-Hodgkin lymphoma (in vivo CAR-T)), guided by the company to H1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: SANA
Next catalyst: H1 2027
Type: Phase 1 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Sana Biotechnology SANA · Nasdaq	SG293	Non-Hodgkin lymphoma (in vivo CAR-T)	H1 2027 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing guides "SG293 in non-Hodgkin lymphoma — potential to share first-in-human data in 1H 2027." Source: 8-K exhibit 99.1, filed 08 Sep 2026 · verified 12 Sep 2026

Companies working on related conditions

Tempest Therapeutics (TPST)Myasthenia gravis / multiple sclerosis (CD7 in vivo CAR-T)
Arvinas (ARVN)KRAS G12D-mutant solid tumours (degrader); Relapsed/refractory non-Hodgkin lymphoma (BCL6 degrader); Parkinson’s disease (LRRK2 degrader) — biomarker data; Kenn
Compass Therapeutics (CMPX)Biliary tract cancer (DLL4 x VEGF-A bispecific); TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1); Solid tumours (PD-1 x VEGF-A bispecific)
Allogene Therapeutics (ALLO)Autoimmune disease (allogeneic CD19/CD70 CAR-T); First-line large B-cell lymphoma consolidation
Caribou Biosciences (CRBU)Relapsed/refractory multiple myeloma (allogeneic BCMA CAR-T)
Cartesian Therapeutics (RNAC)Myasthenia gravis (mRNA CAR-T); Myositis; Juvenile dermatomyositis (paediatric); Myasthenia gravis